TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC cut its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 38.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 323,350 shares of the company’s stock after selling 200,070 shares during the period. TransMedics Group comprises about 2.0% of Emerald Advisers LLC’s portfolio, making the stock its 4th biggest position. Emerald Advisers LLC owned about 0.98% of TransMedics Group worth $48,703,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in TMDX. Fidelis Capital Partners LLC acquired a new position in TransMedics Group during the 1st quarter worth $35,000. International Assets Investment Management LLC purchased a new position in shares of TransMedics Group in the 2nd quarter valued at about $47,000. J.Safra Asset Management Corp grew its position in shares of TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after buying an additional 383 shares in the last quarter. Signaturefd LLC increased its stake in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the period. Finally, Entropy Technologies LP acquired a new stake in TransMedics Group in the first quarter valued at approximately $201,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

TMDX has been the subject of several analyst reports. Oppenheimer boosted their price target on shares of TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Piper Sandler boosted their target price on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Needham & Company LLC initiated coverage on TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 price target on the stock. Stephens lifted their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, TD Cowen increased their price objective on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $171.44.

TransMedics Group Stock Down 2.4 %

TMDX opened at $139.88 on Friday. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $177.37. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. The stock has a market capitalization of $4.67 billion, a P/E ratio of -411.41 and a beta of 1.99. The business’s 50-day simple moving average is $154.82 and its 200-day simple moving average is $124.58.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The firm’s revenue was up 117.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.03) earnings per share. Analysts anticipate that TransMedics Group, Inc. will post 1.21 EPS for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,948,714.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,948,714.31. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $149.96, for a total value of $1,012,230.00. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at $109,770.72. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock worth $9,551,089 in the last 90 days. 7.00% of the stock is owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.